Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

Affiliations

• ¹ Department of Pharmacy, University of Washington, 1959 NE Pacific St, HSB H375-P, Box 357630, Seattle, WA, 98195-7630, USA.
• ² Division of Cardiology, Stony Brook University, Stony Brook, NY, USA.
• ³ CMD Consulting, Sandy, UT, USA.
• ⁴ Magellan Rx, Salt Lake City, UT, USA.
• ⁵ Epidemiology, HEOR and Observational Research, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA.
• ⁶ Department of Clinical Pharmacy, University of California, San Francisco, CA, USA.
• ⁷ University of Michigan School of Medicine, Ann Arbor, MI, USA.
• ⁸ Division of Cardiology, Department of Medicine, Saint Louis University School of Medicine, Saint Louis, MI, USA.
• ⁹ Department of Pharmacy, University of Washington, 1959 NE Pacific St, HSB H375-P, Box 357630, Seattle, WA, 98195-7630, USA. [email protected].